Investigators assessed the therapeutic potential of dihydroceramide desaturase 1 inhibition, the last enzyme involved in de novo ceramide synthesis, to mitigate the vascular effects of the protein-bound uremic toxins indoxyl sulfate
[Vascular Pharmacology]